Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04607330
Other study ID # PROSHT20'
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 28, 2020
Est. completion date June 28, 2022

Study information

Verified date April 2023
Source Nutricia UK Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this prospective, single-arm intervention study is to evaluate the acceptability (compliance, gastrointestinal tolerance, and palatability) to a low calorie, low volume, ready to use, high protein liquid in patients with elevated protein needs.


Description:

Increased protein needs are frequently observed in disease and can be difficult for patients to achieve where oral food intake is compromised.Where a standard ONS or enteral tube feed cannot meet the needs of patients, a modular feed can be added to the regimen, a low calorie, low volume, ready to use, high protein liquid may help meet protein needs while preventing caloric overfeeding. 40 patients will be recruited in an attempt to evaluate the acceptability (compliance, gastrointestinal tolerance, and palatability) to a low calorie, low volume, ready to use, high protein liquid in patients with elevated protein needs. After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance and dietary intake with their currently prescribed nutritional regimen, each patient will receive the high protein liquid feed daily for 28 days.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date June 28, 2022
Est. primary completion date May 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - 18 years of age and older. - Patients under the care of a Dietitian requiring oral or enteral nutritional support, with -increased protein needs. - To receive a minimum of 1 x 40ml HPLM daily (orally or via enteral tube) while on the study. - Informed consent obtained from the patient Exclusion Criteria: - Total parenteral nutrition (100% of requirements). - Patients with major hepatic dysfunction (i.e. decompensated liver disease). - Patients with major renal dysfunction (i.e. requiring filtration or Stage 4/5 chronic kidney disease (CKD)). - Participation in other studies within 1 month prior to entry of this study. - Patient with severe lactose intolerance. - Pregnant or lactating. - Patient lacks capacity to consent for themselves.

Study Design


Intervention

Other:
High protein liquid
After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.

Locations

Country Name City State
United Kingdom University Hospitals Bristol Bristol
United Kingdom Western Sussex Hospitals NHS Trust Worthing West Sussex

Sponsors (1)

Lead Sponsor Collaborator
Nutricia UK Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Acceptability Acceptability of the patients existing feeding regimen (including any protein module use) will be assessed on day 1, baseline period. Acceptability with the study product will be assessed at the end of the intervention period using a standardised questionnaire completed by the patient. 2 days (days 1 and 29)
Secondary Compliance Compliance with the recommended intake of patients' currently prescribed high protein modular feed (if an existing user) and feeding regimen overall will be assessed separately at baseline. Similarly, compliance with the study product will be assessed daily throughout the intervention period and weekly when considering the patients feeding regimen overall. Compliance data will not be used in calculations for nutrient intake. For daily compliance questions, patients will be asked to record how many servings are taken compared to that recommended by their Health Care Professional (HCP). The daily amount prescribed by the HCP managing the patients care will be recorded at the start of the study and any changes to this prescription during the study will be noted. To strengthen compliance measures for the HPLM only, a count of the HPLM will be conducted on day 29 and compared to amount prescribed at baseline. 29 days
Secondary Change in Gastrointestinal tolerance Gastrointestinal tolerance (including symptoms of diarrhoea, constipation, nausea, vomiting, abdominal pain, bloating, flatulence and burping) and information about bowel movements will be assessed during baseline (day 1), and on days 8, 15 and 29 of the intervention period using a standardised gastrointestinal tolerance questionnaire. This will be completed by the patient or their carer (using the scale: none, mild, moderate, severe symptoms) 4 days (day 1, 8, 15 and 29)
Secondary Change in Nutrient Intake (24-hour dietary recall) During recruitment, on a per patient and condition specific basis, the patients managing Dietitians will calculate estimated energy and protein requirements as per standard dietetic practice. Intake of all nutrition provided (including the HPLM, other enteral tube feeds, foods, drinks and oral nutritional supplements) will be recorded at baseline and at the end of the intervention period via 24 hour dietary recall. Actual intakes will subsequently be compared against Dietitians calculated estimated energy and protein requirements and percentage achievements of these requirements will also be calculated. This will include details of feeding regimens as required. Trained research staff will subsequently analyse all records utilising a nutritional software package (Nutritics Professional v3.09, Nutritics, Ireland) for macro- and micro-nutrient intakes. 2 days (day 1 and 29)
Secondary Change in Physical Function (30-s Chair Stand Test) To assess physical function, the 30-s Chair Stand Test will be completed during baseline (day 1) and at the end of the intervention period (day 29). Patients will be requested to stand up and sitting down from a chair as many times as possible within 30 seconds. This will be performed 3 times (with a 1 min rest in between sets) and an average score taken. A standard chair (with a seat height of approximately 40 cm) without armrests will be used. Initially, patients will be seated with their back in an upright position and arms folded across the chest. They will need to look straight forward and begin once ready and maintain their own preferred speed. 2 days (day 1 and 29)
Secondary Change in MUST Screening The risk of malnutrition will be assessed during baseline (day 1) and at the end of the intervention period (day 29) using the Malnutrition Universal Screening Tool (MUST). MUST is a five-step screening tool to identify adults, who are malnourished, at risk of malnutrition (undernutrition), or obese. Trials sites will receive a guide and flowchart to help quantify MUST score. 2 days (day 1 and 29)
Secondary Change in Height Height will be captured, wherever possible, using standard measures to the nearest 0.1cm. 2 days (day 1 and 29)
Secondary Change in Weight Weight will be determined to the nearest 0.1kg, using portable scales, shoeless and wearing light weight clothing. 2 days (day 1 and 29)
Secondary Dietetic Goal The dietetic goal of each patient will be recorded at baseline by the Dietitian and achievement of this goal (via yes/no responses) in the view of the Dietitian will be assessed at the end of the intervention (day 29). 1 day (day 29)
Secondary Adverse events All adverse events will be recorded, throughout the study. 29 days (assessed daily)
Secondary Patient history A detailed patient history will be recorded at baseline to assess previous compliance, relevant clinical issues, diagnosis, medication prescribed, details of current and previous feeding regimens, feeding history, need for protein supplementation and any other relevant clinical information related to the patient's condition or diet. 1 day (day 1)
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Recruiting NCT05993221 - Deconstructing Post Stroke Hemiparesis